The US makes up most of North American demand, accounting for roughly 84-87% of the region in 2025. One forecast sees US growth of about 3.7-4.1% CAGR from 2026 to 2034. Its position rests on specialist diagnostic pathways, neurology access, treatment registries and structured reimbursement for advanced therapies. The main shift to 2034 is from symptomatic drugs such as cholinesterase...